Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid initiation of BIC/FTC/TAF vs EFV + TDF + 3TC in treatment-naïve HIV-1 patients
ChiCTR2400080553Phase 4Not yet recruiting
- Sponsor
- Chest Hospital of Guangxi Zhuang Autonomous Region
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Chest Hospital of Guangxi Zhuang Autonomous Region. Primary endpoint: Viral inhibition rate at 24 weeks. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2400080553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080553.